Defining 'T cell exhaustion'
- PMID: 31570879
- PMCID: PMC7286441
- DOI: 10.1038/s41577-019-0221-9
Defining 'T cell exhaustion'
Abstract
'T cell exhaustion' is a broad term that has been used to describe the response of T cells to chronic antigen stimulation, first in the setting of chronic viral infection but more recently in response to tumours. Understanding the features of and pathways to exhaustion has crucial implications for the success of checkpoint blockade and adoptive T cell transfer therapies. In this Viewpoint article, 18 experts in the field tell us what exhaustion means to them, ranging from complete lack of effector function to altered functionality to prevent immunopathology, with potential differences between cancer and chronic infection. Their responses highlight the dichotomy between terminally differentiated exhausted T cells that are TCF1- and the self-renewing TCF1+ population from which they derive. These TCF1+ cells are considered by some to have stem cell-like properties akin to memory T cell populations, but the developmental relationships are unclear at present. Recent studies have also highlighted an important role for the transcriptional regulator TOX in driving the epigenetic enforcement of exhaustion, but key questions remain about the potential to reverse the epigenetic programme of exhaustion and how this might affect the persistence of T cell populations.
Conflict of interest statement
Competing interests
W.N.H. is an employee of Merck & Co. and a founder of Arsenal Biosciences. The La Jolla Institute for Immunology (LJI) has received a research grant from Lyell lmmunopharma to support aspects of the work of P.G.H. on transcriptional mechanisms in CD8+ T cells. E.L. receives preclinical research funding from Bristol-Myers Squibb. LJI is the recipient of a research grant from Lyell lmmunopharma, which supports studies in the laboratory of A.R. using mouse models to elucidate the transcriptional and epigenetic programmes operating in CD8+ tumour-infiltrating T cells. LJI has a pending patent, PCT/US201B/062354, covering the use and production of engineered immune cells to disrupt NFAT–AP-1 pathway transcription factors, including NR4A1/2/3, TOX and TOX2, with A.R. listed as one of the inventors. LJI is the recipient of a research grant from the Takeda-Sanford Innovation Alliance for research in the laboratory of A.R. related to NR4A in human CD8+ T cells. N.P.R. and R.C.L. are employees of Lyell Immunopharma. A.H.S. has patents on the PD1 pathway licenced by Roche/Genentech and Novartis, consults for Novartis, is on the scientific advisory boards for Surface Oncology, Sqz Biotech, Elstar Therapeutics, Elpiscience, Selecta and Monopteros, and has research funding from Novartis, Roche, Ipsen, UCB, Quark Ventures and Merck. E.J.W. is a member of the Parker Institute for Cancer lmmunotherapy, which supported the present study. E.J.W. has consulting agreements with and/or is on the scientific advisory board for Merck, Roche, Pieris, Elstar and Surface Oncology. E.J.W. has a patent licensing agreement on the PD1 pathway with Roche/Genentech. E.J.W. is a founder of Arsenal Biosciences. B.A.Y. has patents associated with epigenetic programming of T cells. He has received honoraria for speaking at companies (less than US$5,000). The other authors declare no competing interests.
Figures
Similar articles
-
Memory T cell, exhaustion, and tumor immunity.Immunol Med. 2020 Mar;43(1):1-9. doi: 10.1080/25785826.2019.1698261. Epub 2019 Dec 10. Immunol Med. 2020. PMID: 31822213 Review.
-
Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy.Immunity. 2019 Jan 15;50(1):195-211.e10. doi: 10.1016/j.immuni.2018.12.021. Epub 2019 Jan 8. Immunity. 2019. PMID: 30635237
-
Decoding and overcoming T cell exhaustion: Epigenetic and transcriptional dynamics in CAR-T cells against solid tumors.Mol Ther. 2024 Jun 5;32(6):1617-1627. doi: 10.1016/j.ymthe.2024.04.004. Epub 2024 Apr 6. Mol Ther. 2024. PMID: 38582965 Free PMC article. Review.
-
TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection.Nature. 2019 Jul;571(7764):265-269. doi: 10.1038/s41586-019-1326-9. Epub 2019 Jun 17. Nature. 2019. PMID: 31207605
-
Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms.Immunity. 2020 May 19;52(5):825-841.e8. doi: 10.1016/j.immuni.2020.04.014. Epub 2020 May 11. Immunity. 2020. PMID: 32396847 Free PMC article.
Cited by
-
Single-Cell Transcriptomics Reveals Cellular Heterogeneity and Drivers in Serrated Pathway-Driven Colorectal Cancer Progression.Int J Mol Sci. 2024 Oct 11;25(20):10944. doi: 10.3390/ijms252010944. Int J Mol Sci. 2024. PMID: 39456726 Free PMC article.
-
The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing.Mol Ther Methods Clin Dev. 2020 Jun 30;18:571-581. doi: 10.1016/j.omtm.2020.06.024. eCollection 2020 Sep 11. Mol Ther Methods Clin Dev. 2020. PMID: 32775492 Free PMC article.
-
LRP11 promotes stem-like T cells via MAPK13-mediated TCF1 phosphorylation, enhancing anti-PD1 immunotherapy.J Immunother Cancer. 2024 Jan 25;12(1):e008367. doi: 10.1136/jitc-2023-008367. J Immunother Cancer. 2024. PMID: 38272565 Free PMC article.
-
Age-associated remodeling of T cell immunity and metabolism.Cell Metab. 2023 Jan 3;35(1):36-55. doi: 10.1016/j.cmet.2022.11.005. Epub 2022 Dec 5. Cell Metab. 2023. PMID: 36473467 Free PMC article. Review.
-
A unified atlas of CD8 T cell dysfunctional states in cancer and infection.Mol Cell. 2021 Jun 3;81(11):2477-2493.e10. doi: 10.1016/j.molcel.2021.03.045. Epub 2021 Apr 22. Mol Cell. 2021. PMID: 33891860 Free PMC article.
References
-
- Speiser DE et al. T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat. Rev. Immunol 14, 768–774 (2014). - PubMed
-
- Wherry EJ T cell exhaustion. Nat. Immunol 12, 492–499 (2011). - PubMed
-
- McLane LM, Abdel-Hakeem MS & Wherry EJ CD8 T cell exhaustion during chronic viral infection and cancer. Annu. Rev. Immunol 37, 457–495 (2019). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources